|
Synonyms: (formerly orlotamab) | MGD-009 | MGD009
Compound class:
Antibody
Comment: Obrindatamab (MGD009) is a bi-specific mAb-like agent that simultaneously targets the B7 immune regulator B7-H3 (CD276; expressed by many cancers and ) and CD3e (expressed by immune effector cells, and a negative regulator of T-cell activation with a role in immune-evasion, tumour cell invasion and metastasis), that was developed for anti-tumour potential [2]. The mechanism of obrindatamab is to promote the activation and cell-killing functions of immune effector cells and direct this towards the co-engaged tumour cells. Obrindatamab was developed using MacroGenics' proprietary Dual-Affinity Re-targeting (DART®) technology. The peptide sequences for the heavy and light chains of the B7-H3 binding domains of obrindatamab are claimed in MacroGenics' patent US8802091B2 9SEQ IDs 99 and 89 respectively) [1].
|
| No information available. |
Summary of Clinical Use  |
| MGD009 was advanced to clinical trials in B7-H3-expressing advanced solid tumours. Development appears to have stopped. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03406949 | MGD009/MGA012 Combination in Relapsed/Refractory Cancer | Phase 1 Interventional | MacroGenics | ||
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | Phase 1 Interventional | MacroGenics | ||
